Farmácia/Notícias da Indústria
[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.
15 Jun, 2021 | 11:35hComunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox
Comentário no Twitter (fio – clique para saber mais)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
[Preprint] 2 doses de vacina contra Covid (Pfizer-BioNTech ou Oxford-AstraZeneca) são altamente eficazes contra hospitalização decorrente de infecção pela variante Delta.
15 Jun, 2021 | 11:32hComunicado de imprensa: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Comentário no Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— Public Health England (@PHE_uk) June 14, 2021
M-A | Ibuprofeno e outros anti-inflamatórios não hormonais (AINH) são superiores a codeína no manejo da dor pós-cirúrgica de paciente ambulatorial.
15 Jun, 2021 | 11:16hComunicado de imprensa: Ibuprofen and other NSAIDs superior to codeine for managing outpatient postoperative pain – Canadian Medical Association Journal
Pesquisa em laboratório mostra que o soro de pessoas plenamente vacinadas (após 2 doses) com a vacina da Pfizer–BioNTech pode neutralizar efetivamente a variante B.1.617 (Delta) e outras do SARS-CoV-2.
14 Jun, 2021 | 11:24hBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature
Comentário no Twitter
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY
— Carlos del Rio (@CarlosdelRio7) June 12, 2021
O impacto da vacinação sobre as novas infecções por SARS-CoV-2 no Reino Unido – “Não há evidência de diferença entre as vacinas BNT162b2 (Pfizer-BioNTech) e ChAdOx1 (AstraZeneca).”
14 Jun, 2021 | 11:23hImpact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine
Comentários no Twitter
The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO
— Nature Medicine (@NatureMedicine) June 9, 2021
First-dose vaccination with the Oxford–AstraZeneca or Pfizer–BioNTech vaccine against SARS-CoV-2 reduced the incidence of new infections in the UK by 61% and 66%, respectively, according to a study in @NatureMedicine. https://t.co/2TUFE1DeII pic.twitter.com/KuMtc1cD7l
— Nature Portfolio (@NaturePortfolio) June 9, 2021
Estudo randomizado | Em pacientes com COVID-19, não há diferença na mortalidade em 30 dias entre continuar ou descontinuar o uso de inibidores do sistema renina-angiotensina, mas uma análise secundária e exploratória mostrou que tal descontinuação pode levar a uma recuperação melhor e mais rápida.
14 Jun, 2021 | 11:18hEditorial: RAS inhibition and COVID-19: more questions than answers?
Estudos randomizados relacionados mostrando que não há benefício na descontinuação: Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19 E Randomized trial: Renin–angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19
Alta taxa de vacinação contra COVID pode proteger os não vacinados.
11 Jun, 2021 | 10:45hHigh COVID vaccine uptake may protect the unvaccinated – CIDRAP
Estudo original: Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals – Nature Medicine
Comentários no Twitter
Just published @NatureMedicine
Evidence that "vaccination not only protects individuals who have been vaccinated but also provides cross-protection to unvaccinated individuals in the community" as seen in kids benefiting from high % of adults vaxxedhttps://t.co/IPQo6WTFZX pic.twitter.com/jtfD93onnn— Eric Topol (@EricTopol) June 10, 2021
Nature Medicine: "On average, for each 20% increase in the number of vaccinated people in a given population, the number of positive SARS-CoV-2 tests in the unvaccinated population in the same community decreased approximately two fold." https://t.co/QhMqSbZDtc
— Niklas Fagerström (@niklasf) June 10, 2021
Perspectiva | A vacinação de adultos impede que as crianças também disseminem a COVID?
11 Jun, 2021 | 10:44hDoes vaccinating adults stop kids from spreading COVID too? – Nature
Segundo a OMS, a doação dos EUA de 500 milhões de doses da vacina da Pfizer pode ajudar a “virar o jogo” num momento em que a África enfrenta falta de doses.
11 Jun, 2021 | 10:43hCDC afirma que casos de inflamação cardíaca em pessoas de 16 a 24 anos depois da segunda dose da vacina contra Covid foram acima do esperado, mas, ainda assim, raros.
11 Jun, 2021 | 10:42hVer também: CDC plans “emergency meeting” on rare heart inflammation following COVID-19 vaccines – CBC News
Relacionado: Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men.